The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Open accessAbstract
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surgical resection is recognized worldwide as the preferred treatment for patients with early stage HCC, whereas liver transplantation is indicated in those with early stage disease who are not deemed suitable for resection7,22.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, regimens including immune-checkpoint inhibitors (ICIs) are currently adopted as first-line therapies in clinical guidelines7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, clinical decisions are based on clinical factors including, but not limited to, performance status, tumour burden, liver function and comorbidities7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Now the positive results of IMbrave 050 (ref. 12) have led to a revised management algorithm for patients with early stage HCC by incorporating adjuvant therapies in this disease setting7 (Fig. 4).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
InfluentialMazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”
Research works printed but not linked: 2
- Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
- Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057
Cited by
Sorted by citations
Items 601–700 of 1,000
Abdelhamed, W., & El‐Kassas, M. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.138 · Cited by 5
Patel, A., Daher, D., Yekkaluri, S., Ng, M., Rich, N. E., & Singal, A. G. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.05.010 · Cited by 5
Self-citationMatono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14224 · Cited by 5
Xu, X., Wu, H., Gu, L., Zhao, Y.-Z., Zhou, Y.-H., Chen, T., Guo, H.-W., Chen, Z., Lin, K., Gu, W.-M., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18213-9 · Cited by 5
Gene therapy for people with hepatocellular carcinoma
Naing, C. M., Ni, H., Aung, H. H., Htet, N. H., & Nikolova, D. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013731.pub2 · Cited by 4
Lee, S. W., Kang, M. K., & Zhang, X. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.09.12 · Cited by 5
Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001834 · Cited by 7
Self-citationKobayashi, K., Ogasawara, S., Itobayashi, E., Okubo, T., Itokawa, N., Nakamura, K., Moriguchi, M., Watanabe, S., Ikeda, M., Kuroda, H., et al. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01441-3 · Cited by 4
Li, X., Cao, K., Fu, Z., Chen, X., Zhong, J., Liu, L., Ding, N., Zhang, X., Qu, Z., Zhu, L., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s488734 · Cited by 4
“11 The criteria for inclusion were outlined as below: (a) aged 18–75 years; (b) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2; (c) HCC with Vp4 PVTT diagnosed on the basis of imaging evidence (MRI/CT) supplemented by necessary clinical and laboratory information; (d)…”
Interventional oncology and immunotherapy: current status and future perspectives
Ma, J., Wei, Z., & Ye, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541105 · Cited by 4
Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis at US Safety-Net Health Systems
Wong, R. J., Jones, P. D., Niu, B., Pinheiro, P. S., Thamer, M., Kshirsagar, O. S., Zhang, Y., Fass, R., Therapondos, G., Singal, A. G., et al. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000877 · Cited by 4
“Major society guidelines recommend HCC surveillance in patients with cirrhosis using abdominal ultrasound (US) and alpha fetoprotein every 6 months (8,9).”
Self-citationPerlberger, G., Barialei, I., Lalov, L., Bracke, B., de Beeck, B. O., Tannouri, F., & Chapelle, T. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110292 · Cited by 4
Asiri, M. S., BinAbdu, A., Alammar, A., Alsuaib, A. A., Al-Shehri, A., Al-Mazyad, A. S., Aloufi, A., Al-Gazlan, N. S., Alrajih, H. S., Alkaiyat, M., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s525984 · Cited by 4
Prognostic and predictive imaging markers of hepatocellular carcinoma: a pictorial essay
Deyirmendjian, C., Padda, B., Fowler, K. J., Chernyak, V., Sirlin, C. B., Jiang, H., Vu, K., Dadour, J. R., Murphy-Lavallée, J., Billiard, J.-S., et al. (2025) · Insights into Imaging · doi:10.1186/s13244-025-02058-7 · Cited by 4
Sequeira, L. M., Ying, X., Öztürk, N. B., Reidy, D., Jesudian, A. B., & Gurakar, A. O. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176006 · Cited by 4
“In contrast, for HCV patients without cirrhosis who achieve SVR, HCC risk is so low that surveillance has been demonstrated to cost-ineffective and is not recommended by the AASLD [7,9].”
Yang, J., Lim, J., Kim, E. H., An, J., Lee, D., Lee, H. C., Jeong, J., & Shim, J. H. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s537216 · Cited by 4
CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy
Lee, S., Huang, Y.-J., Lin, Y., Tsai, H., Chen, C., Chang, C., Lee, T., & Peng, Y. (2025) · Cancers · doi:10.3390/cancers17183058 · Cited by 4
“Inclusion criteria included age ≥ 20 years, histologically or radiologically confirmed HCC based on the AASLD criteria [18], received at least one cycle of immunotherapy, availability of serum AFP and PIVKA-II levels at baseline and 4 weeks post-treatment initiation, and adequate clinical follow-up…”
Viering, O., Brosch-Lenz, J., Bundschuh, R. A., Scholtissek, H., Enke, J. S., Amerein, A., Wienand, G., Dierks, A., Kircher, M., Patt, M., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270267 · Cited by 4
Hattenhauer, T., Mispelbaum, R., Heine, A., Schwab, K., Brossart, P., Klümper, N., & Saal, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599143 · Cited by 4
Lee, Y., Wang, J. J., Danpanichkul, P., Kim, H.-S., Kuo, A., Ayoub, W. S., Trivedi, H. D., Wang, Y. F., Vipani, A., Martin, P., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.012 · Cited by 4
Self-citationChen, D., Pan, J., Yao, L., Guo, J., Wang, Z., Ma, H., Ren, H., Zhang, G., Cao, Y., Wang, S., et al. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.10.026 · Cited by 4
Hepatocellular carcinoma: new insights into prevention and surveillance
Jarrah, M., Bourque, S., Choudhury, A. K., & Singal, A. G. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2584018 · Cited by 4
“…from the AASLD, EASL, and the Asian Pacific Association for the Study of the Liver (APASL) recommend semiannual HCC surveillance using abdominal ultrasound with or without alpha-fetoprotein (AFP) to increase early-stage HCC detection, curative treatment receipt, and overall survival [66,67,75].”
Self-citationHwang, S., Shin, D. J., Kang, B., Kang, H., Lee, S. H., Kim, J. S., Joung, J., Jain, S., Olsen, S. R., Becker, L., et al. (2025) · Liver Cancer · doi:10.1159/000549565 · Cited by 4
“Primary liver cancer is the third leading cause of cancer-related death globally, and hepatocellular carcinoma (HCC) is the most common primary liver cancer, constituting approximately 80% of cases [1, 2].”
Self-citationCao, F., An, C., Li, S., Hu, X., Li, D., Pan, J., Geng, Z., Gao, F., & Zuo, M. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02100-4 · Cited by 4
Cai, Z., Li, J., Wu, L., Hu, X., Lin, W., Peng, B., Chen, H., Yang, Q., Li, B., Li, G., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149150 · Cited by 4
Liver disease in people living with HIV infection: a changing landscape
Lee, F., & Bansal, M. B. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01149-6 · Cited by 7
“Abdominal ultrasounds are the most easily accessible and cheapest radiographic mode; unfortunately, the sensitivity and specificity for abdominal ultrasounds in detecting HCC are mediocre (61% and 92%, respectively) 153 .”
Early screening for liver cancer must be performed
Liu, Z., Wang, W., & Dang, S. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i11.112675 · Cited by 5
Meng, F., Nian, F., Feng, H., Chen, Z., Jiang, Q., Zhang, F., Xu, L., Chen, Y., Zhang, H., Tao, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07040-x · Cited by 4
“Immune check-point inhibitors (ICIs) combined with targeted therapies has been incorporated into the 2024 liver cancer management guidelines as a first line treatment regimen [5].”
Dirjayanto, V. J., Yiu, D. C., Chen, R., & Fan, K. H. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70186 · Cited by 4
Singal, A. G., Toyoda, H., Tanwandee, T., Tangkijvanich, P., Tan, C., Cua, I. H., Alcantara‐Payawal, D., Su, T., Huy, N. D. S., Yamada, H., et al. (2025) · Liver Cancer · doi:10.1159/000550100 · Cited by 4
“…guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Asia-Pacific Association for the Study of the Liver (APASL) recommend hepatocellular carcinoma (HCC) surveillance using bi-annual ultrasound plus alpha-fetoprotein (AFP) in high-risk individuals [6, 7].”
Self-citationHao, S., Yao, H., Yu, H., Wang, L., Yu, T., Xia, H., & Zha, Y. (2025) · Liver Research · doi:10.1016/j.livres.2025.11.004 · Cited by 4
“38 Studies have demonstrated that key rate-limiting enzymes in the glycolysis pathway, such as hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase (PK), are significantly upregulated in HCC. 39 This upregulation signifies a pronounced Warburg effect, 40 resulting in elevated lactic acid production in HCC t…”
InfluentialYang, J., Hwang, Y., Ju, J., Han, S., An, J., & Shim, J. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001695 · Cited by 5
Yang, X., Deng, L.-W., Zhao, Y., Peng, B., Liu, B., Feng, S.-F., Liu, D., Liu, J.-F., Sun, Y.-Y., Chen, Y., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11052-0 · Cited by 4
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 6
“250 The precise incidence at different stages and cost-effectiveness considerations do not currently justify such a generalised surveillance approach.”
Tseng, T., Huang, S., & Kao, J.-H. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000915 · Cited by 4
“[8,13] Similarly, the WHO 2024 HBV guidance recommends ultrasound with AFP every 6 months, emphasizing programmatic feasibility and integration into primary care.”
Yazarkan, Y., Sönmez, G., Sahin, T. K., Rizzo, A., & Güven, D. C. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2648127 · Cited by 5
“Surveillance is also recommended in selected chronic HBV populations when the annual HCC risk is ≥0.2% positive or indeterminate results warrant multiphase CT or MRI [50].”
InfluentialThe versatile interplay between steatotic liver disease and liver cancer
Rahbari, M., Gris‐Oliver, A., Ramadori, P., Aicher, D., Sia, D., MALEK, N. P., Loomba, R. S., Bataller, R. A., Llovet, J. M., & Heikenwälder, M. F. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00918-y · Cited by 4
“4 Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS-Hospital Clínic Barcelona, Universitat de Barcelona, Barcelona, Spain.”
InfluentialSelf-citationMASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Ha, S., Zhang, X., Lan-juan, L., & Yu, J. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.04.048 · Cited by 7
Jung, Y. J., Choi, S. H., Heo, S., Kim, D. E., Kim, S., & Hong, S. B. (2026) · American Journal of Roentgenology · doi:10.2214/ajr.26.34591 · Cited by 4
Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach
Allaire, M., Taddei, T. H., Thabut, D., & García–Tsao, G. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01209-5 · Cited by 4
“In these cases, ablation is generally preferred over resection 8,9,11 (Table 1), although advances in minimally invasive surgical laparoscopic techniques have allowed resection in well-selected patients with CSPH 39,40”
InfluentialSelf-citationCho, C. Y., Kim, G. H., Ko, E., Kim, J., Sung, C., Kim, J. H., & Gwon, D. I. (2026) · Korean Journal of Radiology · doi:10.3348/kjr.2026.0156 · Cited by 4
“All patients were diagnosed with HCC according to the American Association for the Study of Liver Diseases criteria [1].”
Ali, M. F., Ahmad, H., Maloth, A. K., Kumar, H., Ramadan, Y., Malik, M. S., Qadeer, T., Khan, M., Mohmand, M. S., Joshi, S., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02044-w · Cited by 4
Kudo, M., Ogasawara, S., Liu, R., Gu, S., Wang, K., Zhao, M., Hu, H., Liu, Z., 林科灿, Liu, J., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00212-8 · Cited by 4
Diagnosis and management of indeterminate liver nodules in patients with cirrhosis
Kanneganti, M., & Singal, A. G. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000069 · Cited by 4
Self-citationCorbett, V., Li, D., & Chauhan, A. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-372 · Cited by 4
“Given the risk of bleeding with bevacizumab, one proposed strategy is to preferentially use the STRIDE regimen in patients at the highest risk of bleeding or with contraindications to bevacizumab for other reasons (10).”
BackgroundMethodInfluentialLiu, B., Liu, J., Mei, X., Zhang, Z., Fang, J., Zhou, L., Zheng, J., Lin, H., Zhu, X.-L., & Li, D. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s442487 · Cited by 4
Inoue, M., Ogasawara, S., Kobayashi, K., Okubo, T., Itokawa, N., Obu, M., Fujimoto, K., Unozawa, H., Yumita, S., Fujiwara, K., et al. (2024) · Liver Cancer · doi:10.1159/000539380 · Cited by 4
Hatanaka, T., Saito, N., Kakizaki, S., Hiraoka, A., Tada, T., Kariyama, K., Tani, J., Takaguchi, K., Itobayashi, E., Ishikawa, T., et al. (2024) · Oncology · doi:10.1159/000541002 · Cited by 4
Fu, C., Chen, H., Chen, Y., Liu, W., & Cao, G. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.103 · Cited by 4
Ito, T., Shimose, S., Tani, J., Tomonari, T., Saeki, I., Takeuchi, Y., Hatanaka, T., Sasaki, K., Kakizaki, S., Kanayama, Y., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14151 · Cited by 4
Zhao, Z., Jiang, X., Wen, S., & Hao, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1499269 · Cited by 4
Meng, X., Qu, X., Guo, Y., Qi, X., Bian, L., Wu, D., Wang, J., Pan, X., Zhou, Y., Chen, F., et al. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.111936 · Cited by 4
Hao, H., Zhang, Y., Yan, M., 夏吉凯, Wang, M., Tian, G., Lv, H., Liu, K., & Zhang, G. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159882 · Cited by 4
Decharatanachart, P., Poovorawan, K., Tangkijvanich, P., Charatcharoenwitthaya, P., Peeraphatdit, T. B., Taychakhoonavudh, S., Treeprasertsuk, S., & Chaiteerakij, R. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003332 · Cited by 4
LI-RADS for Diagnosing Hepatocellular Carcinoma in Patients with Noncirrhotic Chronic Hepatitis C
An, J., Park, R., Kim, E., Na, S. K., Kim, H. I., Song, I. H., Cho, Y. S., Kang, J. H., Lee, H. C., Han, S., et al. (2025) · Radiology · doi:10.1148/radiol.241856 · Cited by 4
Dual-antibody functionalized transistor biosensor for specific diagnosis of liver cancer
Yu, Y., Zhang, W., Ding, Q., Cheng, X., Wang, K., Zhang, G., Jiang, B., Yu, X., Li, Y., & Zhang, G.-J. (2025) · Talanta · doi:10.1016/j.talanta.2025.128095 · Cited by 4
Elgedawy, G. A., Elabd, N. S., Elbrolosy, A. M., El-Morshedy, S. M., Elgamal, A., Abozeid, M., Abdelkreem, M., Eleowa, S. S., & Helal, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01625-y · Cited by 4
“The diagnosis of HCC was based on the characteristic triphasic CT findings of arterial-phase enhancement and portal/delayed washout [29].”
Haruna, Y., Yakushijin, T., Yamakawa, M. Y., & Nakazawa, T. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03022-4 · Cited by 4
“…have been employed to treat HCC, including resection, percutaneous ablation, transarterial che-moembolization (TACE), liver transplantation, multi-targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and anti-vascular endothelial growth factor (VEGF) or its receptor [2 – 4].”
Tan, H.-Y., Liu, S., Liu, Y., Dai, G.-H., Zheng, J.-L., & Feng, H.-G. (2025) · Discover Oncology · doi:10.1007/s12672-025-02553-9 · Cited by 4
“While international guidelines recommend ICI-based regimens, such as Atezolizumab plus bevacizumab or Tremelimumab plus durvalumab, as the first-line treatment for unresectable HCC with PVTT [4–6], more aggressive approaches have shown promise in improving outcomes [7].”
da Fonseca, L. G., Piñero, F., Anders, M., Bermúdez, C., Demirdjian, E., Varón, A., Perez, D., Rodriguez, J., Beltrán, O., Ridruejo, E., et al. (2025) · Oncotarget · doi:10.18632/oncotarget.28721 · Cited by 4
CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort
Law, W., Zheng, J., Kim, T., Horvat, N. D. S. M. R., Harding, J. J., Sigel, C., Arslan, M. E., Wei, A. C.-C., Do, R. K., & Chernyak, V. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05044-1 · Cited by 4
“However, unlike other malignancies, the diagnosis of the majority of HCCs is established based on imaging alone using Liver Imaging Reporting and Data Systems (LI-RADS, LR) v2018 criteria in a high risk population [6].”
Self-citationHCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment
Patel, S. A., Kasem, F., Flaherty, D. T., & Barve, A. J. (2025) · BioChem · doi:10.3390/biochem5030019 · Cited by 4
Choi, G. H., Kim, H., Luu, M., Kuo, A., Ayoub, W. S., Trivedi, H. D., Wang, Y., Vipani, A., Chen, P., Miles, S. A., et al. (2025) · Liver Cancer · doi:10.1159/000547230 · Cited by 4
Self-citationQin, J., Si, L.-W., Liu, Y., Huang, X., Du, R.-J., Xiong, F., Wang, D., & Zhu, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114231 · Cited by 4
Park, M.-S., Cho, J. Y., Kim, E., Na, H. Y., Choi, Y., Kim, N. R., Yoon, Y., Lee, B., Jang, E. S., Jung, Y. K., et al. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.08.05 · Cited by 4
“175 Similarly, the European Association for the Study of the Liver (EASL) advocates a risk-based approach, emphasizing the use of ultrasonography, CT, or MRI combined with α -FP testing every 3-6 months during the initial 2 years to reduce mortality and enhance cost-effectiveness in HCC management.”
Park, J. H., Goh, M. J., Sinn, D. H., Shin, J., & Rhee, H. (2025) · European Radiology · doi:10.1007/s00330-025-12040-y · Cited by 4
Pan, C. Q., Saadi, S. M., Ghany, M. G., Feld, J. J., Lim, J. K., Kim, A. Y., Tang, A. S., Nguyen, M. H., Sulkowski, M. S., Terrault, N. A., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001584 · Cited by 4
Kuzuya, T., Muto, H., Tachi, Y., Kobayashi, M., Sugiyama, H., Ariga, M., Morisaki, S., Komura, G., Nakano, T., Tanaka, H., et al. (2025) · Cancers · doi:10.3390/cancers17243891 · Cited by 4
“Systemic therapy for unresectable hepatocellular carcinoma (HCC) has advanced markedly in recent years, with immune checkpoint inhibitor (ICI)-based combinations [1–3] now established as the standard first-line treatment [4–6].”
Hund, H. C., Du, L., Matsuoka, L. K., Sze, D. Y., Kennedy, A. S., Golzarian, J., Gandhi, R. T., Collins, Z. S., & Brown, D. B. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.08.039 · Cited by 4
Self-citationChen, S., Qiu, Y., Zhang, Q., Lu, X.-Y., Huang, Y., Dong, Y., & Wang, W. (2023) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2023.08.022 · Cited by 4
Hsu, H.-M., Tsai, H., Lee, W., Wang, C., Yu, M., Lin, S., Lin, C., Wu, C., & Lee, C. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s433598 · Cited by 4
“21 Due to superior survival outcome over sorafenib, Atezo/Bev is the recommended first-line therapy for this subgroup of advanced-stage HCC. 10,11,13,14 The ORR could reach 27%, and the adverse events were mostly tolerable.”
BackgroundScoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma
Ritaccio, G., Barritt, A. S., Conklin, J., Richardson, D. R., Evon, D. M., Sanoff, H. K., Basch, E., Wheeler, S. B., & Moon, A. M. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03167-1 · Cited by 4
Proper assessment and prognostication of patients with hepatocellular carcinoma
Giannini, E. G. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000129 · Cited by 4
Tamaki, N., Higuchi, M., Keitoku, T., Yamazaki, Y., Uchihara, N., Suzuki, K., Tanaka, Y., Miyamoto, H., Yamada, M., Okada, R., et al. (2024) · JGH Open · doi:10.1002/jgh3.13067 · Cited by 4
Updates in liver transplantation policy for patients with hepatocellular carcinoma (HCC)
Mehta, N. J. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000157 · Cited by 4
Self-citationApproach to immunotherapy for HCC in the liver transplant population
Block, P. D., Strazzabosco, M., & Jaffe, A. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000158 · Cited by 4
“[5]”
Influential“Very early” intrahepatic cholangiocarcinoma (≤ 2.0 cm): MRI manifestation and prognostic potential
Sheng, R., Zheng, B., Zhang, Y., Sun, W., Yang, C., Ding, Y., Zhou, J., & Zeng, M. (2024) · Clinical Radiology · doi:10.1016/j.crad.2024.05.005 · Cited by 4
SPONTANEOUS REGRESSION OF HEPATOCELLULAR CARCINOMA: FOCUSING IN THE ASSOCIATED RISK FACTORS
Tovo, C. V., Ribas, C. R., SARTORI, G. D. P., Coral, G. P., Suwa, E., & de Mattos, Â. A. (2024) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612023-151 · Cited by 4
Liver health in hemophilia in the era of gene therapy
Dargaud, Y. G., Levrero, M., Bailly, F., Lienhart, A., & Zoulim, F. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109064 · Cited by 4
Yu, J., Bai, Y., Cui, Z., Cheng, C., Ladekarl, M. B., Cheng, K., Chan, K. S., Yarmohammadi, H., Mauriz, J. L., & Zhang, Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-315 · Cited by 4
“However, even with R0 resection, the recurrence rate of the disease is still as high as 50% to 70% at 5 years after surgery (5).”
Jo, H.-S., Park, P., Yu, Y., Choi, Y. J., Yu, S. H., & Kim, D. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-578 · Cited by 4
“The recently updated Barcelona Clinic Liver Cancer (BCLC) and American Association for the Study of Liver Diseases (AASLD) guidelines also classified HCC with PVI as an advanced stage and suggested systemic treatments as the first line of treatment (6,7).”
InfluentialLim, N., Devuni, D., German, M. N., Guy, J. E., Rabiee, A., Sharma, P., Shingina, A., Shroff, H., & Pillai, A. A. (2024) · Hepatology · doi:10.1097/hep.0000000000001036 · Cited by 5
Suárez, M., Martínez-Blanco, P., Gil-Rojas, S., Torres, A., Torralba, M., & Mateo, J. (2024) · Bioengineering · doi:10.3390/bioengineering11080762 · Cited by 4
“Furthermore, it also justifies the well-established utility of BCLC classification as a diagnostic, prognostic, and therapeutic reference in various clinical guidelines [8,9].”
BackgroundSurgical approach to hepatocellular carcinoma: a review
Ruff, S. M., & Pawlik, T. M. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2024.52 · Cited by 4
Mukozu, T., Nagai, H., Nagumo, H., Mohri, K., Yoshimine, N., Kobayashi, K., Ogino, Y., Matsui, T., Daido, Y., Wakui, N., et al. (2024) · Oncology · doi:10.1159/000541372 · Cited by 4
Li, Z., Chen, I. C.-Y., Centonze, L., Magyar, C. T. J., Choi, W. J., Shah, S., O'Kane, G. M., Vogel, A., Carlis, L. G. D., Lerut, J. P., et al. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000501 · Cited by 4
“[1,2] Despite careful patient selection, HCC recurs in 6% – 18% of recipients of transplants, [3 – 6] significantly impacting survival, with a median of only 10 – 13 months after recurrence.”
Self-citationHai, L., Bai, X.-Y., Luo, X., Liu, S.-W., Ma, Z.-M., Ma, L., & Ding, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444091 · Cited by 7
Zhang, Y.-W., Zhao, C., Su, B.-J., Lin, W., Liu, W., Liang, J., Shao, C., Cheng, N., & Chen, J. (2024) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2024.152382 · Cited by 4
Scheau, A.-E., Jurcă, S. O., Scheau, C., & Lupescu, I. G. (2024) · Applied Sciences · doi:10.3390/app14209159 · Cited by 4
Tang, Y., Sasaki, S., Hawley, J., Peillon, A., Sjöström, A., Fuentes‐Alburo, A., & Tranquart, F. (2024) · Journal of Clinical Ultrasound · doi:10.1002/jcu.23879 · Cited by 4
“Small HCC is characterized as a primary tumor measuring ≤ 2 or 3 cm in diameter [41], indicative of an early stage of the disease.”
Okumura, T., Kimura, T., Ichikawa, Y., Iwadare, T., Wakabayashi, S., Kobayashi, H., Yamashita, Y., Uchida, T., Pydi, S. P., Tanaka, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76532-5 · Cited by 4
“…made when a nodular lesion was detected by ultrasonography or when tumor markers such as α-fetoprotein and des-γ-carboxyprothrombin were elevated during follow-up, in accordance with the American Association for the Study of Liver Diseases practice guidelines for HCC surveillance and diagnosis 13 .”
Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With Cirrhosis
Vo, T. D., Hoai, S., & Lam, H. T. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002097 · Cited by 4
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma
Guarneri, V., Loggi, E., Ramacieri, G., Serra, C., Vukotic, R., Vitale, G., Scuteri, A., Cursaro, C., Margotti, M., Galli, S., et al. (2025) · Cancers · doi:10.3390/cancers17020167 · Cited by 4
“Additionally, the American Association for the Study of Liver Diseases (AASLD) guidelines suggest the optional use of a combination of US and of alpha-fetoprotein (AFP) [11,12].”
Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC
Jin, L., Dai, H., Zhang, Y., Ou, G., Liang, Z., Lu, Y., & Li, H. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299678 · Cited by 4
“10 Determining the optimal second-line treatment is complicated by clinical trial designs, etiological variability, complications, and patient quality of life.”
Swaroop, S., Biswas, S., Mehta, S., Aggarwal, A., Arora, U., Agarwal, S., Chavan, A., Nayak, B., & Shalimar, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14031034 · Cited by 5
Brahmania, M., Congly, S. E., Sachar, Y., Burak, K. W., Lethebe, B. C., Szostakiwskyj, J. M. H., Lautner, D., Medellin, A., Bhayana, D., Wong, J., et al. (2025) · Liver International · doi:10.1111/liv.70020 · Cited by 4
Lu, C.-H., Kao, W., Wu, C., Ting, W.-Y., Lu, C.-H., Chuang, K.-I., Ni, C.-F., Hsieh, Y., Wu, M., Su, C., et al. (2025) · Liver Cancer · doi:10.1159/000546185 · Cited by 4
“Notably, after the failure of two consecutive TACE procedures, further TACE is unlikely to confer any clinical bene fi t, necessitating transition to systemic therapy [17].”
SBRT for bridging and downstaging HCC before transplant
Li, Z., Yan, M., Claasen, M. P. A. W., Rajendran, L., Magyar, C. T. J., Saha, S., Lee, C., Selzner, N., Jaeckel, E., Ghanekar, A., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101451 · Cited by 4
Self-citationJayawardena, T., Salim, Z., Bertot, L. C., Bunney, J., Demasi, N., Vallve, J., Adams, L. A., Jeffrey, G. P., Speers, D. J., MacQuillan, G. C., et al. (2025) · Liver International · doi:10.1111/liv.70154 · Cited by 4
Peng, N., Mao, L., Su, J., Liu, S., Ou, J., Chen, S., Su, Z., Li, W., Yang, F., Zhou, Y.-H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593153 · Cited by 4
“Although patients have undergone curative surgery or ablation treatment, the 5-year recurrence rate of HCC remains as high as 50 - 70% (21).”
Metadata
- Authors
- Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University Health Network (CA)
- Oregon Health & Science University (US)
- Northwestern Medical Faculty Foundation (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Vanderbilt University Medical Center (US)
- Medical College of Wisconsin (US)
- Stanford Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Corresponding author
- Singal, Amit G.
- ORCID
- Venue
- Hepatology
- Published
- 2023-05-22
- Volume
- 78
- Issue
- 6
- Pages
- 1922-1965
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10663390
- OpenAlex
- W4377011124
- Cited by
- 2,052
- References
- 341
- Citations by year
- 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
- FWCI
- 346.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Boston Scientific Corporation
- Exelixis
- Incyte
- Cancer Research UK (26813)
- Eisai
- Ipsen
- Sirtex Medical
- National Institutes of Health (UL1TR001863)
- Genentech
- National Cancer Institute (P50CA062924, R01CA285544)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
- MeSH terms
- Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
